This is a randomized , double-blind , placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor ( HR ) - positive/human epidermal growth factor receptor 2 ( HER2 ) - negative operable breast cancer .